Introduction {#sec1_1}
============

Frontotemporal dementia (FTD) may be as common as Alzheimer\'s disease (AD) in early-onset neurodegenerative dementia before the age of 60 years \[[@B1]\]. It has three clinical subtypes distinguished by their clinical presentation: behavioral-variant FTD (bvFTD), presenting with a progressive deterioration in social functioning and personality, and two language variants, semantic dementia (SD) with semantic anomia and progressive nonfluent aphasia (PNFA) with effortful, halting, and agrammatic speech \[[@B2],[@B3],[@B4],[@B5],[@B6],[@B7]\]. Up to 14% of patients with FTD might show symptoms overlapping with those of motor neuron disease (MND) \[[@B8]\].

A few epidemiological studies on FTD showed a wide variety of results according to their recruitment setting, such as whether they were clinic based or community based \[[@B1],[@B9],[@B10],[@B11],[@B12],[@B13],[@B14],[@B15],[@B16],[@B17],[@B18],[@B19]\]. These differences in epidemiology may also vary according to ethnic populations. However, there are only limited epidemiological data on FTD available from Asian populations \[[@B13],[@B16],[@B17]\].

The Clinical Research Center for Dementia of South Korea (CREDOS), a government-funded dementia research project conducted by dementia specialists from neurological and psychiatric clinics, initiated a longitudinal registry study on FTD (the CREDOS-FTD study) in 2010, in addition to a CREDOS registry study on AD and vascular dementia \[[@B20]\].

In our study, we explored the demographic, neuropsychological, and neuropsychiatric characteristics of a large group of Korean FTD patients from the CREDOS-FTD registry. The purpose was to identify significant variations in epidemiology among Korean patients with FTD compared with those among Caucasian or other Asian populations. To our knowledge, this is the first nationwide hospital-based registry study of FTD in Korea.

Materials and Methods {#sec1_2}
=====================

Participants {#sec2_1}
------------

Sixteen neurological clinics across Korea participated in this CREDOS-FTD registry study. All patients enrolled in this study met the research criteria for FTD proposed by Knopman et al. \[[@B21]\] and were subclassified into bvFTD, SD, or PNFA. To fulfill the clinical criteria for the FTD subtypes, the patients were first required to have a predominance of a frontal or temporal lobe cognitive/behavioral syndrome without or with only insignificant anterograde amnesia and visuospatial impairment within the first 2 years of symptoms. Additionally, imaging studies demonstrating focal cerebral atrophy of at least one of the following were required: the anterior temporal lobes, the frontal lobes, and the insula or caudate nuclei. Thus, all patients underwent brain MRI, and almost half of the patients were examined by \[^18^F\]fluoro-2-deoxy-D-glucose PET. Patients who had clinical and electrophysiological evidence of MND were classified as having 'MND plus syndrome' (MND-plus) regardless of their clinical subtypes of FTD. The disease severity was assessed by the FTD-specific Clinical Dementia Rating (FTD-CDR), including 2 domains (i.e., behavior and language) in addition to the 6 standardized domains of the CDR \[[@B21]\].

All patients were evaluated by comprehensive interviews, neurological examinations, and neuropsychological assessment, as described elsewhere \[[@B20]\]. In brief, caregivers were interviewed in depth by neurologists and neuropsychologists. Patients with current or past neurological or psychiatric illnesses such as schizophrenia, epilepsy, brain tumors, encephalitis, or severe head trauma were excluded. Patients with physical illnesses that could interfere with the clinical study, such as hearing or vision loss, severe cardiac disorders, severe respiratory illnesses, malignancy, or hepatic or renal disorders, were excluded. Blood tests to exclude secondary causes of dementia included a complete blood count, blood chemistry tests, vitamin B~12~/folate, syphilis serology, and thyroid functioning tests. Conventional brain MRI scans confirmed the absence of structural lesions such as tumors, traumatic brain injuries, hydrocephalus, or severe white matter hyperintensities.

Clinical Evaluations {#sec2_2}
--------------------

We used the FTD Evaluation Package developed by CREDOS, which is composed of the Clinical Evaluation Form and the Caregiver Questionnaire Form. The Clinical Evaluation Form includes the following: (1) a history of cognitive decline from the caregiver, (2) a Mini-Mental State Examination (MMSE) score \[[@B22]\], (3) an FTD-CDR sum of boxes (FTD-CDR SB) score \[[@B21]\], (4) a Global Deterioration Scale (GDS) score \[[@B23]\], (5) a Hachinski Ischemia Scale (HIS) score \[[@B24]\], (6) a neurological examination, (7) a Geriatric Depression Scale score \[[@B25]\], and (8) a Unified Parkinson\'s Disease Rating Scale (UPDRS) Part III score \[[@B26]\].

The Caregiver Questionnaire Form includes each of the following: (1) basic demographic data about the patient and caregiver, (2) a lifestyle and family history, (3) a past medical history including vascular risk factors, (4) a Korean Dementia Screening Questionnaire (KDSQ) score \[[@B27]\], (5) a Barthel ADL index \[[@B28]\], (6) a Seoul Instrumental ADL (SIADL) score \[[@B29]\], (7) a Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI) score \[[@B30]\], (8) a Frontal Behavioral Inventory (FBI) score \[[@B31]\], and (9) a Frontal Executive Dysfunction, Disinhibition, and Apathy Scale (FEDAS) score \[[@B32]\].

We categorized the presenting symptoms of the patients into one of the following three types: abnormal behavior, aphasia, and motor disturbance. In addition to the family history of dementia, we investigated whether patients had a family history of Parkinson\'s disease, MND, or psychiatric disorders.

A committee that included 5-10 dementia specialists held a quarterly meeting to review the clinical histories and brain imaging results of all cases enrolled in this study and to reach a consensus which ascertained the clinical diagnosis. The institutional review boards at all participating centers approved this study, and informed consent was obtained from the patients and caregivers.

Neuropsychological Assessment {#sec2_3}
-----------------------------

All patients underwent a standardized neuropsychological test battery known as the cognitive test battery for FTD (FTD-Cog), consisting of subdomains assessing attention, language and related function, visuospatial function, memory, and frontal/executive function (table [1](#T1){ref-type="table"}). We constructed an FTD-Cog Score of a maximum of 312 points derived from the results of the FTD-Cog tests which is the sum of each subdomain, with 8/312 points (2%) from attention, 90/312 (29%) from language and related function, 37/312 (12%) from visuospatial function, 60/312 (19%) from memory, and 117/312 (38%) from frontal/executive function.

The attention domain score was derived from only the raw score for backward digit span. The raw scores of the Korean version of the Boston Naming Test (K-BNT) \[[@B33]\] and of the Global Language Index (GLI) of the Screening Test for Aphasia and Neurologic Communication Disorders (STAND) -- the latter of which was the sum of the scores for the 6 subtests of picture description (3), naming (4), auditory comprehension (10), repetition (3), reading (7), and writing (3) -- made up the score of the language and related function domain.

The copy test from the Rey Complex Figure Test (RCFT) and a letter cancellation test were administered to evaluate visuospatial function. The letter cancellation test was drawn from the Seoul Neuropsychological Screening Battery (SNSB) \[[@B34]\] and rated '1' if a patient performed normally or '0' if a patient showed hemispatial neglect or any errors.

The memory function score resulted from the sum of 3 recall trials, a delayed-recall task, and a recognition task from the Seoul Verbal Leaning Test (SVLT). Frontal/executive function was evaluated using a motor impersistence test, a contrasting program test, a go/no-go test, a fist-edge-palm task, and a Luria loop task, each of which were rated on a 0-3 scale. In addition, a category word fluency test, a Stroop color-reading test, a verbal similarities test, digit symbol substitution tasks from the Korean Wechsler Adult Intelligence Scale (K-WAIS) \[[@B35]\], and a Korean version of the Trail Making Test for the elderly (K-TMT-e) \[[@B36]\] were administered. Regarding word fluency, a category word generation task (animal) and a phonemic word fluency task ('ㄱ' /g/) were conducted, with a maximum score of 20 for the category word generation task and of 15 for the phonemic word generation task. Thus, if the number of appropriate words generated was greater than 20 or 15, respectively, the measure was scored as 20 or 15 points. The Stroop color-reading test score was converted to a maximum score of 20 by dividing the number of correct responses by 5 and rounding down to the nearest whole number. Five verbal similarities subtests were chosen from the K-WAIS, and the maximum score of each subtest was 2. For the K-TMT-e, the time in seconds (B) needed to complete part B was recorded. Since 60 s was the average time needed for a normal elderly subject to finish part B, 60 was divided by B and then multiplied by 20 to determine the conversion score. The digits after the decimal points were dropped. If B was shorter than 60 s, 60/B was regarded as 1, and if B was longer than 3,000 s, 60/B was regarded as 0.

Results {#sec1_3}
=======

Demographics {#sec2_4}
------------

Two hundred patients were initially enrolled in the CREDOS-FTD registry between January 2010 and March 2012. Eleven patients with uncertain clinical diagnoses were excluded from the analysis to ensure data set homogeneity. The remaining 189 patients were composed of 78 bvFTD (41.3%), 70 SD (37.0%), 33 PNFA (17.5%), and 8 MND-plus patients (4.2%) who showed various presenting symptoms (2 with both aphasia and motor impairment, 3 with abnormal behavior, and 3 with motor impairment). The sexes were equally divided between all subtypes (p = 0.959). The age at onset (p = 0.049) and the age at diagnosis (p = 0.029) differed between the diagnostic subtypes; however, there were no significant differences in duration and education between the diagnostic subgroups (p = 0.238 and p = 0.762, respectively).

A history of dementia in first-degree relatives (parents and siblings) was found in 20.9% (24/115) of the patients with FTD. Even though there was no significant difference in family history between the three subtypes, the PNFA group was less likely to have a positive family history of dementia (9.1%) than the bvFTD (25%) and the SD (23.3%) groups. Only 2 and 5 patients with FTD had a positive family history of Parkinson\'s disease and psychiatric disease, respectively. No patient with FTD demonstrated a family history of MND. In terms of ADL, the MND-plus group showed significantly impaired functional abilities as assessed by the SIADL and KDSQ compared with both the PNFA and SD groups, but not compared with the bvFTD group. Of the four groups, physical ADL were most significantly impaired in the MND-plus group (p = 0.009; table [2](#T2){ref-type="table"}).

Neuropsychological Test Results {#sec2_5}
-------------------------------

The patients with bvFTD showed a significantly better performance on the K-MMSE compared with the SD group (p = 0.013). The patients with PNFA also had better K-MMSE scores than the SD group, although the difference was not significant. The CDR (p = 0.008) and the CDR SB (p = 0.039) scores were significantly the highest in patients with MND-plus. However, there were no significant differences in FTD-CDR SB and GDS scores between the four groups (p = 0.056 and p = 0.056, respectively). Figure [1](#F1){ref-type="fig"} shows the results from the 5 subdomains of the FTD-Cog for the four groups. The SD group had a significantly poorer language function than both the bvFTD (p \< 0.001) and PNFA groups (p \< 0.001). The PNFA patients showed a significantly more impaired language function than the bvFTD patients (p = 0.049). While the memory function of the SD patients was impaired in relation to the bvFTD and PNFA patients, their visuospatial function was greater than that of the bvFTD and PNFA patients. Regarding attention, no differences were seen between the groups. The MND-plus group had a poorer performance than all others in all cognitive domains (table [2](#T2){ref-type="table"}; fig. [1](#F1){ref-type="fig"}). The FTD-Cog total scores differed significantly between the groups (p \< 0.001). Post hoc analyses revealed that the FTD-Cog total scores were significantly higher in the bvFTD group compared with the SD and the MND-plus groups, but not compared with the PNFA group.

Neuropsychiatric and Motor Symptoms {#sec2_6}
-----------------------------------

On the CGA-NPI, the bvFTD group scored significantly higher (more abnormal behavior) than the PNFA and the SD groups (p \< 0.001). However, on the FBI and FEDAS, the bvFTD group showed more behavioral abnormality than the PNFA group but was not different from the SD group. The PNFA patients had more parkinsonian symptoms, which were measured by the UPDRS motor scale, than the bvFTD and SD patients (p = 0.011; table [2](#T2){ref-type="table"}).

Discussion {#sec1_4}
==========

This is the first large epidemiological study in Asian FTD patients, though there have been three demographic FTD studies from Asian countries \[[@B13],[@B16],[@B17]\]. An epidemiologic study from Japan introduced a community-based trial and three hospital-based surveys of the type-specific prevalence of dementia, simply revealing the prevalence of FTD compared with that of AD and the proportion of each subtype of FTD without specific demographic, clinical, or neuropsychological data \[[@B13]\]. A recent study from China reviewed the clinical, demographic, and neuropathological features of 49 Chinese patients with FTD who had been previously reported on \[[@B17]\]. Kang et al. \[[@B16]\] investigated the survival of 121 Korean FTD patients from a single large neurological clinic in Korea, which therefore may not be representative of the true Korean FTD population.

One of the main observations of our study was that the proportion of SD (37.0%) was similar to that of bvFTD (41.3%). Even though Hodges et al. \[[@B6]\] reported that they found 110 SD patients in a sample of 304 FTD patients, which is a percentage similar to that found in our study, this proportion of SD cases is higher than that reported in most other series, in which bvFTD was the most common subtype, accounting for over half to three quarters of the FTD cases, whereas language variants were much less common \[[@B11],[@B13],[@B14],[@B16],[@B17],[@B18],[@B19]\]. The discrepancy in the proportions of FTD subtypes between our and other studies may be due to varying clinical settings. Chow et al. \[[@B37]\] compared referral patterns for FTD patients between specialized FTD clinics and standard AD clinics and demonstrated that language-variant FTD patients more often tended to be referred to specialist clinics. We assume that patients with bvFTD may be more frequently referred to psychiatric clinics than neurological clinics, while language-variant FTD patients are more frequently referred to neurological clinics. The centers that participated in the CREDOS-FTD registry study were all Korean neurological clinics specializing in dementia. In addition, specialists may identify SD more easily, since its clinical features and neuroimaging results tend to be homogeneous compared with other FTD subtypes.

In our study, the sex ratios were almost equal for all diagnostic subtypes. Although a few previous studies found a male predominance in patients with bvFTD and SD or a female predominance in all FTD subtypes \[[@B13],[@B14],[@B16]\], most large series had an equal gender distribution as in our study \[[@B10],[@B37]\]. The age at onset in our study differed between the clinical subtypes. The PNFA patients were slightly older at onset than the bvFTD and SD patients, which was similar to previous reports \[[@B11],[@B14],[@B16],[@B17]\].

Previous studies reported that the prevalence of a positive family history of dementia in first-degree relatives of FTD patients ranged from 20 to 50%. More than 30% of FTD patients in Western countries had a positive family history \[[@B10],[@B11]\], while lower proportions were seen among Asian FTD patients \[[@B13],[@B16],[@B17]\]. In our study, approximately 20% of the patients with FTD had a family history of dementia. Furthermore, a family history of MND, idiopathic Parkinson\'s disease, or psychiatric disease was quite rare in our series.

The strength of the CREDOS-FTD registry study is that we assessed the FTD subjects using an optimized neuropsychological test (the FTD-Cog test). First, although the demographic factors including sex ratio, education, and disease stage measured by the FTD-CDR were not significantly different between the clinical subtypes, the MMSE score was lower in the language variants of FTD, particularly SD, unlike the results from Western countries \[[@B14]\]. This may be due to the heavy dependence on language skills in the MMSE \[[@B38]\]. Second, regarding the results of the FTD-Cog test, the SD subjects had a significantly poorer performance in the language and memory subdomains than the other two subgroups. These findings may be due to the deficits in single-word comprehension and verbal semantic knowledge in SD \[[@B39],[@B40],[@B41]\]. SD patients generally have a good day-to-day episodic memory; however, the verbal memory test may not reflect its preservation. Third, in contrast, visuospatial function (as assessed by the copy test of the RCFT) was selectively preserved in the SD group, which is compatible with the classic diagnostic criteria for SD \[[@B2]\]. A previous report suggests that PNFA patients have preserved visuospatial function \[[@B41]\]; however, a remarkably poor performance was evident in our study.

Here, we applied three behavioral measures to detect abnormal behaviors in FTD, and the results from each questionnaire were similar. The patients with bvFTD demonstrated the most severe behavioral deficits of the three groups, followed by the SD patients. The PNFA group showed the least behavioral abnormalities. These results support previous descriptions suggesting that SD is associated with behavioral abnormalities early in the course of the disease similar to those observed in bvFTD, which is likely due to anatomic involvement of the ventromedial frontal area (orbitofrontal area) as well as the anterior temporal pole in the early stage of SD \[[@B41],[@B42],[@B43]\]. Given that PNFA frequently evolves into corticobasal syndrome or progressive supranuclear palsy, it is not surprising that, among the three groups, the frequency and severity of parkinsonism as assessed by the UPDRS motor scale were highest in the PNFA group \[[@B44],[@B45]\].

Our study has limitations in that the clinical diagnoses of our patients have not been pathologically confirmed. Also, we acknowledge that there might have been some referral bias, since all 16 centers participating in our study were neurological clinics. However, our study is the first to describe the clinical, demographic, neuropsychological, and behavioral characteristics of a large population of Asian FTD patients by an optimized assessment.

This study was supported by grants from the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020 and A120182).

![Neuropsychological function of the four FTD subgroups on the FTD-Cog test. Raw scores are converted to percentages of the maximum score. \* p \< 0.05 by post hoc analyses between the groups.](dee-0004-0242-g01){#F1}

###### 

The FTD-Cog and constructed FTD-Cog Score

  FTD-Cog                                      FTD-Cog Score (maximum points)
  -------------------------------------------- -------------------------------------
  Attention                                    Attention (8)
   Digit span, forward and backward             Digit span, backward (8)
  Language and related function                Language and related function (90)
   K-BNT                                        K-BNT (60)
   STAND                                        GLI of the STAND (30)
  Visuospatial function                        Visuospatial function (37)
   RCFT, copy                                   RCFT, copy (36)
   Letter cancellation                          Letter cancellation (1)
  Memory                                       Memory (60)
   SVLT, free/delayed recall                    SVLT, free/delayed recall (48)
   SVLT, recognition                            SVLT, recognition (12)
  Frontal/executive function                   Frontal/executive function (117)
   Motor impersistence                          Motor impersistence (3)
   Contrasting program                          Contrasting program (3)
   Go/no-go                                     Go/no-go (3)
   Fist-edge-palm                               Fist-edge-palm (3)
   Luria loop                                   Luria loop (3)
   Category word fluency, animal/supermarket    Category word fluency, animal (20)
   Phonemic word fluency ()                     Phonemic word fluency (ㄱ) (15)
   Stroop test, word/color reading              Stroop test, color reading (20)
   Verbal similarities                          Verbal similarities (10)
   Digit symbol substitution                    Digit symbol substitution (17)
   Trail Making                                 Trail Making (20)

The maximum FTC-Cog Score is 312.

###### 

Comparison of demographic, neuropsychological, and neuropsychiatric data on FTD patients

                                                FTD (n = 189)        bvFTD (n = 78)                                                                                                        SD (n = 70)                                                                          PNFA (n = 33)                                                                        MND-plus (n = 8)                                                                                                    p value
  --------------------------------------------- -------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------- ---------
  Male                                          55.6%                57.7%                                                                                                                 54.3%                                                                                54.5%                                                                                50.0%                                                                                                               0.959
  Age at onset, years                           63.4 ± 8.9 (189)     62.1 ± 9.9 (78)                                                                                                       64.7 ± 6.8 (70)                                                                      65.3 ± 9.2 (33)                                                                      58.0 ± 10.5 (8)                                                                                                     0.049
  Age at diagnosis, years                       66.2 ± 8.7 (189)     64.9 ± 9.3 (78)                                                                                                       67.8 ± 7.4 (70)                                                                      67.6 ± 8.8 (33)                                                                      60.0 ± 10.0 (8)                                                                                                     0.029
  Duration, years                               3.0 ± 2.1 (189)      3.1 ± 2.3 (78)                                                                                                        3.4 ± 1.9 (70)                                                                       2.5 ± 2.3 (33)                                                                       2.5 ± 1.2 (8)                                                                                                       0.238
  Education, years                              9.3 ± 5.4 (186)      9.5 ± 5.8 (78)                                                                                                        9.2 ± 5.1 (68)                                                                       9.7 ± 5.5 (32)                                                                       7.5 ± 3.9 (8)                                                                                                       0.762
  Family history                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
   Dementia                                     20.9% (24/115)       25% (12/48)                                                                                                           23.3% (10/43)                                                                        9.1% (2/22)                                                                          0% (0/2)                                                                                                            0.389
   IPD                                          1.1% (2/189)         0% (0/78)                                                                                                             2.9% (2/70)                                                                          0% (0/33)                                                                            0% (0/8)                                                                                                            0.329
   MND                                          0% (0/188)           0% (0/77)                                                                                                             0% (0/70)                                                                            0% (0/33)                                                                            0% (0/8)                                                                                                            \-
   Psychiatric disease                          2.6% (5/189)         3.8% (3/78)                                                                                                           1.4% (1/70)                                                                          0% (0/33)                                                                            12.5% (1/8)                                                                                                         0.053
  K-MMSE score                                  17.6 ± 8.3 (183)     19.6 ± 6.8 (78)[^a^](#T2F1){ref-type="table-fn"}                                                                      15.8 ± 9.4 (68)[^a^](#T2F1){ref-type="table-fn"}                                     17.6 ± 8.6 (30)                                                                      12.3 ± 6.6 (7)                                                                                                      0.013
  CDR score                                     1.0 ± 0.7 (183)      1.0 ± 0.7 (78)[^a^](#T2F1){ref-type="table-fn"}                                                                       1.0 ± 0.7 (68)[^b^](#T2F2){ref-type="table-fn"}                                      0.9 ± 0.7 (29)[^c^](#T2F3){ref-type="table-fn"}                                      1.9 ± 0.8 (8)[^a^](#T2F1){ref-type="table-fn"}[^b^](#T2F2){ref-type="table-fn"}[^c^](#T2F3){ref-type="table-fn"}    0.008
  CDR SB score                                  5.6 ± 4.2 (180)      5.8 ± 4.0 (77)                                                                                                        5.6 ± 4.4 (68)                                                                       4.3 ± 3.8 (27)[^a^](#T2F1){ref-type="table-fn"}                                      9.1 ± 4.7 (8)[^a^](#T2F1){ref-type="table-fn"}                                                                      0.039
  FTD-CDR SB score                              9.3 ± 6.2 (186)      8.8 ± 5.2 (78)                                                                                                        9.7 ± 6.9 (69)                                                                       8.2 ± 6.3 (31)                                                                       14.4 ± 6.0 (8)                                                                                                      0.056
  GDS score                                     4.2 ± 1.1 (178)      4.2 ± 1.0 (77)                                                                                                        4.4 ± 1.1 (66)                                                                       3.8 ± 1.1 (27)                                                                       4.8 ± 0.9 (8)                                                                                                       0.056
  UPDRS score                                   7.8 ± 15.5 (144)     5.3 ± 9.0 (61)[^a^](#T2F1){ref-type="table-fn"}                                                                       6.4 ± 16.9 (52)[^b^](#T2F2){ref-type="table-fn"}                                     17.1 ± 22.5 (25)[^a^](#T2F1){ref-type="table-fn"}[^b^](#T2F2){ref-type="table-fn"}   7.7 ± 6.4 (6)                                                                                                       0.011
  FBI score                                     28.3 ± 16.5 (168)    31.7 ± 15.1 (69)[^a^](#T2F1){ref-type="table-fn"}                                                                     27.5 ± 17.8 (62)                                                                     20.3 ± 15.5 (29)[^a^](#T2F1){ref-type="table-fn"}                                    33.5 ± 13.0 (8)                                                                                                     0.013
  CGA-NPI score                                 21.5 ± 20.3 (173)    29.0 ± 23.5 (73)[^a^](#T2F1){ref-type="table-fn"}[^b^](#T2F2){ref-type="table-fn"}                                    17.2 ± 15.3 (67)[^a^](#T2F1){ref-type="table-fn"}                                    9.3 ± 13.8 (25)[^b^](#T2F2){ref-type="table-fn"}                                     27.8 ± 15.3 (8)                                                                                                     \<0.001
  FEDAS score                                   56.4 ± 30.6 (173)    64.3 ± 26.6 (73)[^a^](#T2F1){ref-type="table-fn"}                                                                     53.6 ± 31.0 (63)                                                                     37.3 ± 31.4 (29)[^a^](#T2F1){ref-type="table-fn"}[^b^](#T2F2){ref-type="table-fn"}   76.5 ± 24.3 (8)[^b^](#T2F2){ref-type="table-fn"}                                                                    \<0.001
  KDSQ score                                    14.5 ± 7.7 (176)     15.2 ± 7.4 (76)                                                                                                       14.6 ± 7.1 (63)                                                                      11.1 ± 8.6 (29)[^a^](#T2F1){ref-type="table-fn"}                                     20.5 ± 7.7 (8)[^a^](#T2F1){ref-type="table-fn"}                                                                     0.009
  SIADL score                                   17.5 ± 12.4 (176)    19.5 ± 11.6 (77)                                                                                                      15.3 ± 12.2 (63)[^a^](#T2F1){ref-type="table-fn"}                                    13.1 ± 12.7 (28)[^b^](#T2F2){ref-type="table-fn"}                                    30.3 ± 8.7 (8)[^a^](#T2F1){ref-type="table-fn"}[^b^](#T2F2){ref-type="table-fn"}                                    0.001
  Barthel ADL index                             18.2 ± 3.4 (181)     18.0 ± 3.0 (77)[^a^](#T2F1){ref-type="table-fn"}                                                                      18.8 ± 3.4 (66)[^b^](#T2F2){ref-type="table-fn"}                                     18.4 ± 3.8 (30)[^c^](#T2F3){ref-type="table-fn"}                                     14.5 ± 4.9 (8)[^a^](#T2F1){ref-type="table-fn"}[^b^](#T2F2){ref-type="table-fn"}[^c^](#T2F3){ref-type="table-fn"}   0.009
  FTD-Cog total score \[312\]                   103.3 ± 67.6 (184)   126.3 ± 70.5 (77)[^a^](#T2F1){ref-type="table-fn"}[^b^](#T2F2){ref-type="table-fn"}                                   88.3 ± 57.2 (68)[^a^](#T2F1){ref-type="table-fn"}                                    93.7 ± 68.0 (31)                                                                     47.5 ± 47.3 (8)[^b^](#T2F2){ref-type="table-fn"}                                                                    \<0.001
   FTD-Cog attention \[[@B8]\]                  2.6 ± 3.9 (161)      3.1 ± 5.7 (70)                                                                                                        2.5 ± 1.6 (59)                                                                       1.8 ± 1.3 (27)                                                                       2.0 ± 1.6 (5)                                                                                                       0.480
   FTD-Cog language \[90\]                      37.7 ± 23.9 (174)    52.0 ± 23.4 (73)[^a^](#T2F1){ref-type="table-fn"}[^b^](#T2F2){ref-type="table-fn"}[^c^](#T2F3){ref-type="table-fn"}   22.4 ± 13.4 (65)[^a^](#T2F1){ref-type="table-fn"}[^d^](#T2F4){ref-type="table-fn"}   40.6 ± 22.2 (28)[^b^](#T2F2){ref-type="table-fn"}[^d^](#T2F4){ref-type="table-fn"}   20.7 ± 16.6 (8)[^c^](#T2F3){ref-type="table-fn"}                                                                    \<0.001
   FTD-Cog visuospatial function \[[@B37]\]     21.5 ± 13.0 (169)    21.0 ± 12.7 (72)[^a^](#T2F1){ref-type="table-fn"}                                                                     25.7 ± 11.1 (61)[^b^](#T2F2){ref-type="table-fn"}[^c^](#T2F3){ref-type="table-fn"}   17.6 ± 13.7 (28)[^b^](#T2F2){ref-type="table-fn"}                                    7.6 ± 13.7 (8)[^a^](#T2F1){ref-type="table-fn"}[^c^](#T2F3){ref-type="table-fn"}                                    \<0.001
   FTD-Cog memory \[60\]                        12.7 ± 9.4 (165)     16.3 ± 9.0 (72)[^a^](#T2F1){ref-type="table-fn"}[^b^](#T2F2){ref-type="table-fn"}                                     8.7 ± 7.5 (58)[^a^](#T2F1){ref-type="table-fn"}                                      13.3 ± 10.3 (27)                                                                     7.6 ± 10.1 (8)[^b^](#T2F2){ref-type="table-fn"}                                                                     \<0.001
   FTD-Cog frontal/executive function \[117\]   34.7 ± 27.9 (183)    39.3 ± 27.8 (77)[^a^](#T2F1){ref-type="table-fn"}                                                                     34.6 ± 28.6 (67)                                                                     29.6 ± 26.2 (31)                                                                     9.8 ± 10.4 (8)[^a^](#T2F1){ref-type="table-fn"}                                                                     0.022

Values denote means ± SD unless specified otherwise. Figures in parentheses in the table body are available numbers for analysis. Figures in square brackets are maximum scores of the FTD-Cog test.

Scores in each row are significantly different in pairwise comparison (Tukey post hoc test). IPD = Idiopathic Parkinson\'s disease.

Scores in each row are significantly different in pairwise comparison (Tukey post hoc test). IPD = Idiopathic Parkinson\'s disease.

Scores in each row are significantly different in pairwise comparison (Tukey post hoc test). IPD = Idiopathic Parkinson\'s disease.

Scores in each row are significantly different in pairwise comparison (Tukey post hoc test). IPD = Idiopathic Parkinson\'s disease.
